Creators and Guests

With over 30 years in creative marketing and visual storytelling, I’ve built a career on turning ideas into impact. From brand transformation to media production, podcast development, and outreach strategies, I craft compelling narratives that don’t just capture attention—they accelerate growth and drive measurable results.

David Esposito is an experienced health care executive who has built and scaled multiple companies, resulting in successful exits to strategic buyers. He is the former CEO of Armune BioScience, where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017. David was president of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) in 2011. He began his career as a sales representative with Merck & Co. Inc., rising through the ranks of sales, marketing and commercial strategy for the U.S. division. As a combat veteran, David led an infantry platoon with the 101st Airborne Division through several combat operations and was recognized with a Bronze Star for combat action in Iraq in 1991. He earned his bachelor’s degree in civil engineering from the U.S. Military Academy at West Point and his MBA from Syracuse University.

Dr. Alena Butkevica, MD, DMD, PhD, is an Oral and Maxillofacial Surgeon and specialist in Prosthodontics and Implantology with over 28 years of clinical experience and more than 15,000 surgical procedures performed; she is also the CEO and founder of AB BIOINNOVATIONS, Inc. (AB BIO), a U.S.-based biotechnology company developing science-backed products that reset, restore, and enhance the body’s natural regenerative abilities by improving circulation, releasing toxins, and accelerating healing—an approach rooted in Dr. Butkevica’s 19 years of scientific research in fast and healthy tissue regeneration.

Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new drugs in model organisms called evolutionary pharmacology. Ethan is an author on 19 peer-reviewed scholarly publications, including the discovery of a novel mechanism of action for the antidepressant Zoloft based on studies in yeast cells.

Jessica Gibson is the CEO and Co-Founder of Ariel Precision Medicine, dedicated to delivering innovative technology to advance the art and science of Precision Medicine. Ariel leverages expert systems to accelerate precision medicine across the healthcare ecosystem by linking diagnostics and patient-centered data, uncovering the mechanisms of disease, and developing targeted treatments—fundamentally transforming patients' lives and outcomes. With a strong record of leadership, Jessica brings creative and solution-oriented problem-solving skills to accomplish strategic goals. At Ariel, she applies a broad range of experience across the pharmaceutical, biotechnology, clinical, and research sectors to develop scalable solutions for some of healthcare's most pressing challenges in chronic disease. Highly driven and grounded in a strong foundation of medical sales and marketing, Jessica is committed to collaborative engagement with diverse stakeholders, always with a patient-focused perspective.

Medical device sales professional that utilizes grit, achievement drive, and organization to achieve success and appropriate solutions for the customer. High achievement with highest revenue, President's Club, etc. Strong leadership skills and desire to facilitate the success of others.

Throughout her career, Kerchanin Allen has supported organizations ranging from startups to Fortune 50 companies in operationalizing their marketing and communications strategies, with a focus on compliance and sustainable growth. In her recent roles, she has emphasized leadership in developing comprehensive, health-centric, and value-based marketing strategies that drive success in post-acute care and align with broader business objectives. Kerchanin works collaboratively with cross-functional teams to refine brand storytelling and develop robust, data-driven content pillars and account-based marketing (ABM) strategies that resonate with target audiences and support growth-focused initiatives. Her expertise also extends to leveraging data analytics for campaign optimization and managing budgets to maximize ROI. With a strong command of digital, print, and media channels, along with a talent for cultivating key partnerships, she plays a vital role in advancing brand presence and market influence.